Connect with us
[the_ad id="89560"]

Business

US lawmakers accuse Pfizer, Eli Lilly of testing new drugs on prisoners in Communist China

Published

6 minute read

From LifeSiteNews

By Calvin Freiburger

Two Republicans and two Democrats in the House of Representatives have leveled stunning allegations against two pharmaceutical companies, calling on the U.S. Food and Drug Administration to investigate potential testing of drugs on prisoners of Communist China.

A bipartisan group of Congress members has leveled stunning allegations against pharmaceutical companies Pfizer and Eli Lilly, calling on the U.S. Food & Drug Administration (FDA) to investigate the potential testing of new drugs on prisoners of Communist China.

The letter was sent August 19 to FDA Commissioner Dr. Robert Calf and signed by Select Committee on the Chinese Communist Party (CCP) Chair Rep. John Moolenaar, a Republican from Florida and ranking member and Illinois Democratic Rep. Raja Krishnamoorthi, Health Energy & Commerce Subcommittee ranking member and California Democratic Rep. Anna Eshoo, and Florida Republican Rep. Neal Dunn.

“For over a decade, it appears that U.S. biopharmaceutical companies conducted clinical trials with China’s military organizations, and specifically with medical centers and hospitals affiliated with the People’s Liberation Army’s (PLA), to determine the safety and effectiveness of new drug candidates prior to approval,” the letter reads. “ … we are also concerned that U.S. biopharmaceutical companies have conducted clinical trials with hospital infrastructure located in the Xinjiang Uyghur Autonomous Region (XUAR), where the Chinese Communist Party (CCP) is engaged in genocide of the Uyghur population.”

The lawmakers’ review of publicly available data found that over the last decade major American Pharma companies have conducted “hundreds of clinical trials in China that included at least one entity with PLA in the name as a research trial partner.”

“Even today, one major U.S. biopharmaceutical entity is actively recruiting patients for an advanced Alzheimer drug trial and is partnered with the PLA’s General Hospital and Medical School … and the PLA’s Air Force Medical University. … Previously, another U.S. biopharmaceutical entity used the 307 Hospital of the PLA (307 医院) as the setting for a cancer therapeutic clinical trial.”

Such work not only carries risks of sensitive technology falling into the CCP’s hands, “there are also U.S. biopharmaceutical trials listed on clinicaltrials.gov that were conducted with hospitals located in the XUAR, where credible investigative reports have shown that ethnic minorities in the region are repeatedly forced by the CCP to surrender their body autonomy. As we know, there is simply no ability for firms to conduct due diligence to ensure that clinical trials done in XUAR are voluntary.”

Axios noted that the trials in question concern Pfizer’s kidney cancer drug axitinib (brand name Inlyta), and Eli Lilly’s Alzheimer’s drug donanemab (brand name Kisunla).

The lawmakers asked the FDA to answer several questions related to its knowledge and oversight of such trials and called on the agency to “take on a greater role in protecting U.S. national security interests. With this data, it is clear that the FDA should play a greater role in analyzing U.S. biopharma entities (sic) clinical trial operations in the PRC.”

Pfizer responded that it “is committed to conducting business in an ethical and responsible manner. This includes respecting internationally recognized human rights throughout our operations,” Straight News reported. Eli Lilly claimed that it is “committed to IP protections, and we conduct robust assessments of our partners to ensure they meet Lilly standards for research and data privacy. Further, we oversee their activities when conducting clinical trials to ensure quality and data integrity.”

large body of evidence has found that mass restrictions on personal and economic activity undertaken in 2020 and part of 2021 caused far more harm than good in terms of personal freedom and economics as well as public health, particularly through the controversial COVID vaccines rushed through development by Pfizer, Moderna, Johnson & Johnson, and the Trump administration.

Yet, so far Big Pharma has largely escaped accountability thanks to the federal Public Readiness and Emergency Preparedness (PREP) Act of 2005. According to the Congressional Research Service (CRS), the PREP Act empowers the federal government to “limit legal liability for losses relating to the administration of medical countermeasures such as diagnostics, treatments, and vaccines.” Near the beginning of the 2020 COVID-19 outbreak, the Trump administration invoked the Act in declaring the virus a “public health emergency.”

Under this “sweeping” immunity, CRS explained, the federal government, state governments, “manufacturers and distributors of covered countermeasures,” and licensed or otherwise-authorized health professionals distributing those countermeasures are shielded from “all claims of loss” stemming from those countermeasures, with the exception of “death or serious physical injury” brought about through “willful misconduct,” a standard that, among other hurdles, requires the offender to have acted “intentionally to achieve a wrongful purpose.”

A handful of states are currently making efforts to hold Pharma companies accountable despite this hurdle, such as Florida’s ongoing grand jury investigation into the vaccines’ manufacturers, and a Kansas lawsuit accusing Pfizer of misrepresentation for calling the shots “safe and effective.”

Automotive

Two thirds of Canadians say banning conventional vehicles by 2035 is “unrealistic”

Published on

From the Montreal Economic Institute

Seven in 10 Canadians are concerned about the negative impact of cancelled energy projects on Canadian jobs.

More than half of Canadiens are against the federal mandate forcing all new cars sold in Canada to be electric by 2035, shows a new MEI-Ipsos survey released this morning.

“Across the country, Canadians are a lot more hesitant to ban conventional vehicles than their elected representatives in Ottawa are,” said Krystle Wittevrongel, director of research at the MEI. “They have legitimate concerns, most notably with the cost of those cars, and federal and provincial politicians should take note.”

The poll shows that 55 per cent of Canadians disagree with Ottawa’s decision to ban the sale of conventional vehicles by 2035. In every region surveyed, a larger number of respondents were against the ban than in favour of it.

Among Canadians who don’t already own an electric vehicle, slightly fewer than one in four said their next car would be electric.

Key reasons cited for this lukewarm attitude included the high cost of the cars (70 per cent), the lack of charging infrastructure (66 per cent), and their reduced performance in Canada’s cold climate (64 per cent).

Across the country, only 26 per cent of Canadians believe Ottawa’s plan to ban the sale of conventional vehicles is realistic. Meanwhile, 66 per cent maintain that the plan is unrealistic.

“Canadians understand that 2035 is sooner than Ottawa thinks, and nothing indicates electric vehicle adoption rates are going to follow what federal lawmakers anticipated,” notes Ms. Wittevrongel. “Concerns with their high cost, the lack of charging infrastructure and their poor performance in our cold climate remain strong.”

The survey also found Canadians were troubled by the effects that federal legislation has had in stalling or cancelling energy projects.

Seven in 10 respondents were concerned by the negative impact on Canadian jobs arising from the cancellation of tens of billions of dollars in energy projects due to regulatory hurdles.

Slightly more than three in four Canadians (76 per cent) say the federal government’s environmental impact assessment project takes too long, with only nine per cent taking the opposite view.

“Canadians understand that our energy industry plays a key role in Canada’s economy, and that lengthy approval delays from regulators have a negative impact on a project’s chances of happening,” explains Ms. Wittevrongel. “They are looking for leadership in Ottawa and in the provinces to cut down on bureaucratic hurdles and shorten the time it takes to get shovels in the ground.”

A sample of 1,190 Canadians 18 years of age and older was polled between September 18th and 22nd, 2024. The results are accurate to within ± 3.3 percentage points, 19 times out of 20.

The results of the MEI-Ipsos poll are available here: https://www.iedm.org/wp-content/uploads/2024/10/ipsos_survey_energy_in_canada_september_2024.pdf.

The MEI is an independent public policy think tank with offices in Montreal and Calgary. Through its publications, media appearances, and advisory services to policymakers, the MEI stimulates public policy debate and reforms based on sound economics and entrepreneurship.

 

Continue Reading

Alberta

Alberta rail hub doubling in size to transport plastic from major new carbon-neutral plant

Published on

Haulage bridge at Cando Rail & Terminals’ Sturgeon Terminal in Alberta’s Industrial Heartland, near Edmonton. Photo courtesy Cando Rail & Terminals

From the Canadian Energy Centre

By Will Gibson

Cando Rail & Terminals to invest $200 million to support Dow’s Path2Zero petrochemical complex

A major rail hub in Alberta’s Industrial Heartland will double in size to support a new carbon-neutral plastic production facility, turning the terminal into the largest of its kind in the country.

Cando Rail & Terminals will invest $200 million at its Sturgeon Terminal after securing Dow Chemical as an anchor tenant for its expanded terminal, which will support the planned $8.9 billion Path2Zero petrochemical complex being built in the region northeast of Edmonton.

“Half of the terminal expansion will be dedicated to the Dow project and handle the products produced at the Path2Zero complex,” says Steve Bromley, Cando’s chief commercial officer.

Steve Bromley, chief commercial officer with Cando Rail & Terminals.

By incorporating carbon capture and storage, the complex, which began construction this spring, is expected to be the world’s first to produce polyethylene with net zero scope 1 and 2 emissions.

The widely used plastic’s journey to global markets will begin by rail.

“Dow stores their polyethylene in covered railcars while waiting to sell it,” Bromley says.

“When buyers purchase it, we will build unit trains and those cars will go to the Port of Prince Rupert and eventually be shipped to their customers in Asia.”

A “unit train” is a single train where all the cars carry the same commodity to the same destination.

The expanded Cando terminal will have the capacity to prepare 12,000-foot unit trains – or trains that are more than three-and-a-half kilometers long.

Construction will start on the expansion in 2025 at a 320-acre site west of Cando’s existing terminal, which 20 industrial customers use to stage and store railcars as well as assemble unit trains.

Bromley, a former CP Rail executive who joined Cando in 2013, says the other half of the terminal’s capacity not used by the Dow facility will be sold to other major projects in the region.

The announcement is the latest in a series of investments for Cando to grow its operations in Alberta that will see the company spend more than $500 million by 2027.

The company, which is majority owned by the Alberta Investment Management Corporation previously spent $100 million to acquire a 1,700-railcar facility in Lethbridge along with $150 million to build its existing Sturgeon terminal.

Cando Rail’s existing Sturgeon Terminal near Edmonton, Alberta. Photo courtesy Cando Rail & Terminals

“Alberta is important to us – we have 300 active employees in this province and handle 900,000 railcars annually here,” Bromley says.

“But we are looking for opportunities across North America, both in Canada and the United States as well.”

Cando released the news of the Sturgeon Terminal expansion at the Alberta Industrial Heartland Association’s annual conference on Sept. 19.

“This is an investment in critical infrastructure that underpins additional growth in the region,” says Mark Plamondon, the association’s executive director.

The announcement came as the association marked its 25th anniversary at the event, which Plamondon saw as fitting.

“Dow’s Path2Zero came to the region because of the competitive advantages gained by clustering heavy industry. Competitive advantages are built from infrastructure that’s already here, such as the Alberta Carbon Trunk Line, which transports and stores carbon dioxide for industry,” he says.

“Having that level of integration can turn inputs into one operation into outputs for another. Competitive advantages for one become advantages for others. Cando’s investment will attract others just as Dow’s Path2Zero was a pull for additional investment.”

Continue Reading

Trending

X